✦ LIBER ✦

Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: In vitro and in vivo studies

✍ Scribed by Daigo Akahane; Tetsuzo Tauchi; Seiichi Okabe; Kousuke Nunoda; Kazuma Ohyashiki

Book ID: 108584192
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 451 KB
Volume: 99
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2008.00810.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In vitro anti-myeloma activity of the Au

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465

✍ Joseph M. Negri; Douglas W. McMillin; Jake Delmore; Nicholas Mitsiades; Patrick 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB

Preclinical pharmacokinetics and in vitr

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL

✍ Amrita V. Kamath; Jian Wang; Francis Y. Lee; Punit H. Marathe 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 341 KB

YN968D1 is a novel and selective inhibit

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

✍ Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang Lü; Yongping Xu; Jin 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

YN968D1 is a novel and selective inhibit

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

✍ Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang Lü; Yongping Xu; Jin 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

Angiogenesis is an important process in cell development, especially in cancer. Vascular endothelial growth factor (VEGF) signaling is an important regulator of angiogenesis. Several therapies that act against VEGF signal transduction have been developed, including YN968D1, which is a potent inhibit

Absorption of CH330331, a novel 4-anilin

Absorption of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase: comparative studies using in vitro, in situ and in vivo models

✍ Haiyan Sun; Huichang Bi; Min Huang; Dong Liu; Zhenyu Qin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 1 views

In vitro and in vivo studies of the nove

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor

✍ E. PERZBORN; J. STRASSBURGER; A. WILMEN; J. POHLMANN; S. ROEHRIG; K-H. SCHLEMMER 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 502 KB